COMPANY

BIND Biosciences, Inc. is a biopharmaceutical company leveraging its proprietary Medicinal Nanoengineering™ platform to design, engineer and manufacture highly precise best-in-class targeted therapeutics.  Medicinal Nanoengineering complements medicinal chemistry to enable predictable, cost effective and rapid development of breakthrough products with superior efficacy and safety profiles. Product opportunities include enabling or expediting the development of pipeline molecules as well as improving performance, expanding indications, or life cycle extension for mid- and late-stage products. BIND’s initial product development efforts are in the areas of oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics.  BIND’s lead program, BIND-014, targets a surface protein upregulated in solid tumors and is planned to enter clinical development in 2H 2010.

A targeted nanoparticle must possess the optimal biophysicochemical properties in order to preferentially accumulate in the target tissue, avoid being cleared by the immune system, and deliver the desired drug release profile. By leveraging over fifteen years of innovations in the fields of nanotechnology, materials science and combinatorial synthesis, BIND has developed proprietary enabling technologies that allow us to narrowly define the key characteristics necessary for a maximally effective therapeutic nanoparticle. Using our platform, BIND is able to:

• Engineer nanoparticle libraries with distinct biophysicochemical properties
• Iteratively select and optimize nanoparticles for each application
• Scale-up and manufacture optimized targeted nanoparticles

BIND was launched in 2007 by two pioneers in the field of therapeutic targeted nanoparticles, Dr. Robert Langer, MIT David H. Koch Institute Professor, and Dr. Omid Farokhzad, Harvard Medical School Associate Professor. The company licensed a large patent estate on a worldwide exclusive basis from MIT and Brigham and Women’s Hospital/Harvard Medical School covering the scientific founders’ work in therapeutic targeted nanoparticles.

Our world-class team of management, advisors and investors is rapidly positioning BIND as the leader in the emerging field of nanomedicine. We have assembled a team of experienced drug development experts, many of whom pioneered and commercialized particle-based therapies, including Doxil® and Risperdal Consta®. BIND is backed by a syndicate of top-tier investors including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investment (representing David H. Koch).